TrialJournal for immunotherapy of cancer2021

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).

Natasha B Leighl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.